SubHero Banner
Text

March 2018

Core topics in this month’s edition include:

  • Ilumya (tildrakizumab-asmn) - new drug approval
  • Trogarzo (ibalizumab-uiyk) - new drug approval
  • Praluent (alirocumab) – ODYSSEY outcomes study results

Download PDF

Text